Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SLNO
stocks logo

SLNO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
0.612
-148.21%
--
--
0.685
-172.11%
--
--
0.953
-1158.89%
Estimates Revision
The market is revising Upward the revenue expectations for Soleno Therapeutics, Inc. (SLNO) for FY2025, with the revenue forecasts being adjusted by 27.98% over the past three months. During the same period, the stock price has changed by -24.49%.
Revenue Estimates for FY2025
Revise Upward
up Image
+27.98%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-126.6%
In Past 3 Month
Stock Price
Go Down
down Image
-24.49%
In Past 3 Month
Wall Street analysts forecast SLNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLNO is 118.50 USD with a low forecast of 106.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast SLNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLNO is 118.50 USD with a low forecast of 106.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.680
sliders
Low
106.00
Averages
118.50
High
145.00
Current: 52.680
sliders
Low
106.00
Averages
118.50
High
145.00
Wolfe Research
Kalpit Patel
Outperform
initiated
$75
2025-11-17
Reason
Wolfe Research
Kalpit Patel
Price Target
$75
2025-11-17
initiated
Outperform
Reason
Wolfe Research analyst Kalpit Patel initiated coverage of Soleno Therapeutics with an Outperform rating and $75 price target. Shares have been weak following a slowing of new patient starts quarter-over-quarter, but the firm's survey results suggest that the safety concerns are "overblown" and the directional trend for utilization is favorable for the next one to two years, the analyst tells investors.
Wells Fargo
Derek Archila
Overweight
downgrade
$123 -> $106
2025-11-05
Reason
Wells Fargo
Derek Archila
Price Target
$123 -> $106
2025-11-05
downgrade
Overweight
Reason
Wells Fargo analyst Derek Archila lowered the firm's price target on Soleno Therapeutics to $106 from $123 and keeps an Overweight rating on the shares. The firm says that while this is not the quarter it hoped for exactly, Wells still thinks Vykat XR will be a $1B-plus drug in Prader-Willi syndrome. The firm expects shares to be volatile through year-end 2025 on competitor data but sees the opportunity for shares to outperform on Q4 revenues amid low expectations.
Wells Fargo
Overweight
maintain
$123
2025-09-24
Reason
Wells Fargo
Price Target
$123
2025-09-24
maintain
Overweight
Reason
Wells Fargo believes Acadia Pharmaceuticals' (ACAD) Phase 3 failure removes a near-term competitor to Soleno Therapeutics' (SLNO) VYKAT XR. Wells thinks Soleno's shares should trade up at least 20% on Acadia Pharmaceuticals' failure in PWS, Prader-Willi syndrome. The firm remains bullish on VYKAT's launch and would be a buyer at these levels into Q3 print. Wells has an Overweight rating on Soleno with a price target of $123 on the shares.
Wells Fargo
Overweight
initiated
$123
2025-08-20
Reason
Wells Fargo
Price Target
$123
2025-08-20
initiated
Overweight
Reason
Wells Fargo initiated coverage of Soleno Therapeutics with an Overweight rating and $123 price target. The shares are down 23% this month on concerns over Vykat's satiety, competition and and its recent financing which could be a sign of no near-term takeover, the analyst tells investors in a research note. Wells views the concerns as overblown. Vykat's launch in Prader-Willi syndrome remains early, and the significant unmet should drive meaningful near-term uptake, the analyst tells investors in a research note. Wells recommends buying Soleno shares on the recent pullback.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$100 -> $110
2025-08-18
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$100 -> $110
2025-08-18
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Soleno Therapeutics to $110 from $100 and keeps a Buy rating on the shares. The firm says Citizen Petitions usually do not result in withdrawals of products from the U.S. market, as over 80% of those filed since 2001 have been denied or failed to elicit a response from the FDA. It updated the company's model post the Q2 report.
Oppenheimer
Oppenheimer
Outperform
maintain
$105 -> $110
2025-08-07
Reason
Oppenheimer
Oppenheimer
Price Target
$105 -> $110
2025-08-07
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Soleno Therapeutics to $110 from $105 and keeps an Outperform rating on the shares. The firm notes Vykat XR sales of $32.7M in its first launch quarter came in line with last month's pre-announcement. With a U.S. launch trending toward cash-flow positive and EU sales poised to begin next year, Oppenheimer views Soleno as a highly attractive, clean growth story.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Soleno Therapeutics Inc (SLNO.O) is 15.35, compared to its 5-year average forward P/E of -5.50. For a more detailed relative valuation and DCF analysis to assess Soleno Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.50
Current PE
15.35
Overvalued PE
12.60
Undervalued PE
-23.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.93
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
5.29
Undervalued EV/EBITDA
-3.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
73.54
Current PS
0.00
Overvalued PS
303.34
Undervalued PS
-156.27
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 1314.42% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 1314.42% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

SLNO News & Events

Events Timeline

(ET)
2025-11-11
07:07:24
Soleno Board Approves $100 Million Accelerated Share Buyback Agreement
select
2025-11-05 (ET)
2025-11-05
12:02:12
Soleno Therapeutics Experiences a 29.0% Decline
select
2025-11-05
10:00:09
Soleno Therapeutics Experiences a 26.7% Decline
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
06:42 AMPRnewswire
Soleno Therapeutics Faces Investigation Over VYKAT™ XR Misstatements as Stock Plummets 40%
  • Legal Investigation Initiated: Shareholder rights law firm Johnson Fistel is investigating whether Soleno violated federal securities laws by making false statements regarding VYKAT™ XR, which could undermine investor confidence and lead to significant legal repercussions.
  • Product Launch Challenges: Despite receiving FDA approval for VYKAT™ XR in September 2025, Soleno acknowledged during its November earnings call that it faced challenges such as a slowdown in new treatment initiations and increased therapy discontinuations, indicating potential risks to market acceptance and revenue.
  • Impact of Short Seller Report: In August 2025, short seller Scorpion Capital issued a report questioning the safety and commercialization plans for VYKAT™ XR, resulting in a nearly 40% decline in Soleno's stock price from August 14 to November 5, highlighting investor concerns about the sustainability of its business model.
  • Investor Loss Risk: The significant stock volatility raises concerns for investors who purchased Soleno securities during this period, as they may face substantial losses and potential legal actions, further intensifying the company's financial and reputational challenges.
[object Object]
Preview
7.0
12-04Globenewswire
Agilon Health CEO Resignation Triggers 27% Stock Drop
  • Leadership Transition: On August 4, 2025, Agilon Health, Inc. announced the resignation of CEO Steven Sell, resulting in a more than 27% drop in the company's stock price during after-hours trading, indicating strong market reactions to leadership instability.
  • Guidance Withdrawal: The company also withdrew its full-year 2025 earnings guidance, which surprised the market and exacerbated investor anxiety, potentially impacting future financing capabilities and market confidence.
  • Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating whether Agilon failed to disclose material information related to the leadership transition, which could violate federal securities laws; unfavorable findings could have long-term repercussions on the company's reputation and stock price.
  • Market Reaction: The stock price of Agilon was severely impacted by the leadership changes and guidance withdrawal, leading to investor concerns about the company's future profitability and stability, which may result in further capital outflows.
[object Object]
Preview
5.0
12-04Globenewswire
Soleno Therapeutics Board Member Bill Harris Passes Away, Impacting Governance
  • Board Transition: Soleno Therapeutics announces the passing of William Harris, a board member since 2014, which may impact the company's governance structure and decision-making processes.
  • Audit Committee Leadership: Harris served as Chair of the Audit Committee, with Andrew Sinclair expected to take over, who qualifies as an audit committee financial expert under SEC standards, ensuring continuity in audit functions.
  • Industry Impact: Harris's extensive experience in the biopharmaceutical sector provided crucial guidance to the company, particularly during challenging and opportunistic periods, potentially influencing the company's strategic direction.
  • Future Development Outlook: Soleno is focused on developing novel therapeutics for rare diseases, and Harris's passing may have potential implications for the company's future financing and strategic decisions.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Soleno Therapeutics Inc (SLNO) stock price today?

The current price of SLNO is 52.68 USD — it has increased 3.86 % in the last trading day.

arrow icon

What is Soleno Therapeutics Inc (SLNO)'s business?

Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.

arrow icon

What is the price predicton of SLNO Stock?

Wall Street analysts forecast SLNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLNO is 118.50 USD with a low forecast of 106.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Soleno Therapeutics Inc (SLNO)'s revenue for the last quarter?

Soleno Therapeutics Inc revenue for the last quarter amounts to 66.02M USD, decreased % YoY.

arrow icon

What is Soleno Therapeutics Inc (SLNO)'s earnings per share (EPS) for the last quarter?

Soleno Therapeutics Inc. EPS for the last quarter amounts to 0.47 USD, decreased -125.68 % YoY.

arrow icon

What changes have occurred in the market's expectations for Soleno Therapeutics Inc (SLNO)'s fundamentals?

The market is revising Upward the revenue expectations for Soleno Therapeutics, Inc. (SLNO) for FY2025, with the revenue forecasts being adjusted by 27.98% over the past three months. During the same period, the stock price has changed by -24.49%.
arrow icon

How many employees does Soleno Therapeutics Inc (SLNO). have?

Soleno Therapeutics Inc (SLNO) has 92 emplpoyees as of December 05 2025.

arrow icon

What is Soleno Therapeutics Inc (SLNO) market cap?

Today SLNO has the market capitalization of 2.83B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free